282 related articles for article (PubMed ID: 36707892)
21. Impaired Amyloid Beta Clearance and Brain Microvascular Dysfunction are Present in the Tg-SwDI Mouse Model of Alzheimer's Disease.
Rosas-Hernandez H; Cuevas E; Raymick JB; Robinson BL; Sarkar S
Neuroscience; 2020 Aug; 440():48-55. PubMed ID: 32450297
[TBL] [Abstract][Full Text] [Related]
22. Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease.
Deane R; Bell RD; Sagare A; Zlokovic BV
CNS Neurol Disord Drug Targets; 2009 Mar; 8(1):16-30. PubMed ID: 19275634
[TBL] [Abstract][Full Text] [Related]
23. ABCG2 is upregulated in Alzheimer's brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for Abeta(1-40) peptides.
Xiong H; Callaghan D; Jones A; Bai J; Rasquinha I; Smith C; Pei K; Walker D; Lue LF; Stanimirovic D; Zhang W
J Neurosci; 2009 Apr; 29(17):5463-75. PubMed ID: 19403814
[TBL] [Abstract][Full Text] [Related]
24. Ketone Bodies Promote Amyloid-β
Versele R; Corsi M; Fuso A; Sevin E; Businaro R; Gosselet F; Fenart L; Candela P
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32023814
[TBL] [Abstract][Full Text] [Related]
25. IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor.
Deane R; Sagare A; Hamm K; Parisi M; LaRue B; Guo H; Wu Z; Holtzman DM; Zlokovic BV
J Neurosci; 2005 Dec; 25(50):11495-503. PubMed ID: 16354907
[TBL] [Abstract][Full Text] [Related]
26. Decreasing the expression of PICALM reduces endocytosis and the activity of β-secretase: implications for Alzheimer's disease.
Thomas RS; Henson A; Gerrish A; Jones L; Williams J; Kidd EJ
BMC Neurosci; 2016 Jul; 17(1):50. PubMed ID: 27430330
[TBL] [Abstract][Full Text] [Related]
27. Amylin Enhances Amyloid-β Peptide Brain to Blood Efflux Across the Blood-Brain Barrier.
Mohamed LA; Zhu H; Mousa YM; Wang E; Qiu WQ; Kaddoumi A
J Alzheimers Dis; 2017; 56(3):1087-1099. PubMed ID: 28059785
[TBL] [Abstract][Full Text] [Related]
28. Distribution and expression of picalm in Alzheimer disease.
Baig S; Joseph SA; Tayler H; Abraham R; Owen MJ; Williams J; Kehoe PG; Love S
J Neuropathol Exp Neurol; 2010 Oct; 69(10):1071-7. PubMed ID: 20838239
[TBL] [Abstract][Full Text] [Related]
29. Role of phosphatidylinositol clathrin assembly lymphoid-myeloid leukemia (PICALM) in intracellular amyloid precursor protein (APP) processing and amyloid plaque pathogenesis.
Xiao Q; Gil SC; Yan P; Wang Y; Han S; Gonzales E; Perez R; Cirrito JR; Lee JM
J Biol Chem; 2012 Jun; 287(25):21279-89. PubMed ID: 22539346
[TBL] [Abstract][Full Text] [Related]
30. PCSK9 acts as a key regulator of Aβ clearance across the blood-brain barrier.
Mazura AD; Ohler A; Storck SE; Kurtyka M; Scharfenberg F; Weggen S; Becker-Pauly C; Pietrzik CU
Cell Mol Life Sci; 2022 Mar; 79(4):212. PubMed ID: 35344086
[TBL] [Abstract][Full Text] [Related]
31. Distinct Uptake Kinetics of Alzheimer Disease Amyloid-
Sharda N; Ahlschwede KM; Curran GL; Lowe VJ; Kandimalla KK
J Pharmacol Exp Ther; 2021 Mar; 376(3):482-490. PubMed ID: 33303699
[TBL] [Abstract][Full Text] [Related]
32. Proteasome inhibition protects blood-brain barrier P-glycoprotein and lowers Aβ brain levels in an Alzheimer's disease model.
Vulin M; Zhong Y; Maloney BJ; Bauer B; Hartz AMS
Fluids Barriers CNS; 2023 Oct; 20(1):70. PubMed ID: 37803468
[TBL] [Abstract][Full Text] [Related]
33. The role of LRP1 in Aβ efflux transport across the blood-brain barrier and cognitive dysfunction in diabetes mellitus.
P X; Zz L; Gg J; Lp W; Cm B; Yl W; Chen MF; W L
Neurochem Int; 2022 Nov; 160():105417. PubMed ID: 36067928
[TBL] [Abstract][Full Text] [Related]
34. Blood-Brain Barrier Penetrating Biologic TNF-α Inhibitor for Alzheimer's Disease.
Chang R; Knox J; Chang J; Derbedrossian A; Vasilevko V; Cribbs D; Boado RJ; Pardridge WM; Sumbria RK
Mol Pharm; 2017 Jul; 14(7):2340-2349. PubMed ID: 28514851
[TBL] [Abstract][Full Text] [Related]
35. Influence of Matrix Metallopeptidase 9 on Beta-Amyloid Elimination Across the Blood-Brain Barrier.
Shackleton B; Ringland C; Abdullah L; Mullan M; Crawford F; Bachmeier C
Mol Neurobiol; 2019 Dec; 56(12):8296-8305. PubMed ID: 31209784
[TBL] [Abstract][Full Text] [Related]
36. A lipoprotein receptor cluster IV mutant preferentially binds amyloid-β and regulates its clearance from the mouse brain.
Sagare AP; Bell RD; Srivastava A; Sengillo JD; Singh I; Nishida Y; Chow N; Zlokovic BV
J Biol Chem; 2013 May; 288(21):15154-66. PubMed ID: 23580652
[TBL] [Abstract][Full Text] [Related]
37. Chronic cerebral hypoperfusion alters amyloid-β transport related proteins in the cortical blood vessels of Alzheimer's disease model mouse.
Shang J; Yamashita T; Tian F; Li X; Liu X; Shi X; Nakano Y; Tsunoda K; Nomura E; Sasaki R; Tadokoro K; Sato K; Takemoto M; Hishikawa N; Ohta Y; Abe K
Brain Res; 2019 Nov; 1723():146379. PubMed ID: 31415766
[TBL] [Abstract][Full Text] [Related]
38. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system.
Bell RD; Sagare AP; Friedman AE; Bedi GS; Holtzman DM; Deane R; Zlokovic BV
J Cereb Blood Flow Metab; 2007 May; 27(5):909-18. PubMed ID: 17077814
[TBL] [Abstract][Full Text] [Related]
39. Neprilysin deficiency alters the neuropathological and behavioral phenotype in the 5XFAD mouse model of Alzheimer's disease.
Hüttenrauch M; Baches S; Gerth J; Bayer TA; Weggen S; Wirths O
J Alzheimers Dis; 2015; 44(4):1291-302. PubMed ID: 25408216
[TBL] [Abstract][Full Text] [Related]
40. Dysfunction of the blood-brain barrier in Alzheimer's disease: Evidence from human studies.
Kurz C; Walker L; Rauchmann BS; Perneczky R
Neuropathol Appl Neurobiol; 2022 Apr; 48(3):e12782. PubMed ID: 34823269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
